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Available online 5 March 2016Different neurodegenerative diseases can cause memory disorders and other cognitive impairments. The early de-
tection and the stratiﬁcation of patients according to the underlying disease are essential for an efﬁcient approach
to this healthcare challenge. This emphasizes the importance of differential diagnostics. Most studies compare pa-
tients and controls, or Alzheimer's disease with one other type of dementia. Such a bilateral comparison does not
resemble clinical practice, where a clinician is faced with a number of different possible types of dementia.
Herewe studiedwhich features in structuralmagnetic resonance imaging (MRI) scans could best distinguish four
types of dementia, Alzheimer's disease, frontotemporal dementia, vascular dementia, and dementia with Lewy
bodies, and control subjects.We extracted an extensive set of features quantifying volumetric andmorphometric
characteristics from T1 images, and vascular characteristics from FLAIR images. Classiﬁcation was performed
using a multi-class classiﬁer based on Disease State Index methodology. The classiﬁer provided continuous
probability indices for each disease to support clinical decision making.
A dataset of 504 individuals was used for evaluation. The cross-validated classiﬁcation accuracy was 70.6% and
balanced accuracy was 69.1% for the ﬁve disease groups using only automatically determined MRI features.
Vascular dementia patients could be detected with high sensitivity (96%) using features from FLAIR images.
Controls (sensitivity 82%) and Alzheimer's disease patients (sensitivity 74%) could be accurately classiﬁed
using T1-based features, whereas the most difﬁcult group was the dementia with Lewy bodies (sensitivity
32%). These results were notable better than the classiﬁcation accuracies obtained with visual MRI ratings
(accuracy 44.6%, balanced accuracy 51.6%). Different quantiﬁcation methods provided complementary informa-
tion, and consequently, the best results were obtained by utilizing several quantiﬁcation methods.
The results prove that automatic quantiﬁcation methods and computerized decision support methods are feasi-
ble for clinical practice and provide comprehensive information that may help clinicians in the diagnosis making.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Dementia is a general term to describe a syndrome involving loss of
cognitive abilities. Most often dementia is caused by a progressiveän valtatie 24, 33100, Tampere,
(J. Koikkalainen).
. This is an open access article underneurodegenerative disease. Dementia is a major health issue in our so-
ciety both from the economic and human point of view.
Alzheimer's disease (AD) is themost common type of dementia that
may account for 60–75% of dementia cases. Vascular dementia (VaD)
and dementia with Lewy bodies (DLB) also occur frequently in elderly
patients, while frontotemporal dementia (FTD) is relatively more com-
mon in dementia patients with early onset. Characteristic structural pa-
thologies in these diseases include atrophy of the medial temporal lobethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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brain structure is typically less affected. Absence of medial temporal
lobe atrophy and ﬁndings of infarcts orwhitematter changes are typical
to VaD. The atrophy patterns can be detectedwith T1-weighted images.
Cortical and lacunar infarcts and white matter changes that are typical
to VaD are identiﬁed on T1-weighted images and T2-weighted, dual-
echo Turbo Spin Echo (TSE) or Fluid-Attenuated Inversion Recovery
(FLAIR) images.
Early and accurate differential diagnostics of neurodegenerative
diseases is essential for two reasons. First, it has been shown that early
diagnosis combined with current treatments can delay hospitalization
(Feldman et al., 2009), and the importance of the early diagnosis will
dramatically increase as soon as disease-modifying drugs become
available (Siemers et al., 2015). Second, developing new treatments
requires early and accurate identiﬁcation of correct target populations.
It has been hypothesized that too heterogeneous study populations
may explain the failure of some previous pharmaceutical trials
(Falahati et al., 2014).
The studies on structural MRI that have characterized distinct neuro-
degenerative diseases are mostly based on visual ratings (Barber et al.,
1999; Burton et al., 2009; Meyer et al., 2007; Varma et al., 2002),
volumetry (Meyer et al., 2007; Frisoni et al., 1999; Barber et al., 2000;
Munoz-Ruiz et al., 2012; Ishii et al., 2007), and local morphometry analy-
ses (Munoz-Ruiz et al., 2012; Laakso et al., 2000; Burton et al., 2002; Bar-
ber et al., 2002; Ballmaier et al., 2004; Whitwell et al., 2007; Rabinovici
et al., 2008; Klöppel et al., 2008). Typical ﬁndings on the differences be-
tween different dementia types include: 1) the hippocampal volume
and medial temporal lobe are relatively preserved in FTD as compared
to AD (Duara et al., 1999; Frisoni et al., 1999), 2) FTD-speciﬁc atrophy
of the frontal and temporal lobes (Duara et al., 1999; Varma et al.,
2002; Klöppel et al., 2008), 3) relatively preserved brain anatomy in
DLB as compared to AD and FTD (Meyer et al., 2007; Barber et al., 1999,
2000; Burton et al., 2002, 2009; Kantarci et al., 2012; Ishii et al., 2007;
Whitwell et al., 2007), and 4) extensive white matter changes with
lacunar and cortical infarcts in VaD (Meyer et al., 2007).
There are extensive literature comparing the dementia types with
controls, but far less studies have been done on comparing the different
dementia types with each other. In clinical practice, the actual question
is to determine to which type of dementia a patient with cognitive
complaints should be diagnosed. The guidelines for the early detection
of neurodegenerative diseases (Román et al., 1993; Neary et al., 1998;
McKeith et al., 2005; Dubois et al., 2007; Waldemar et al., 2007;
McKhann et al., 2011) are relatively general and do not provide speciﬁc
and uniform information for accurate differential diagnostics of
neurodegenerative diseases. Therefore, the current diagnostic processes
involve a certain degree of subjective assessment and require signiﬁcant
expertise from clinicians. Automatic image quantiﬁcation methods and
computerized decision support methods are able to objectively extract
lots of information, more than the human eye can see, and evaluate
how the patient data relates to typical data from different dementias.
Such data are likely to be useful in clinical diagnosis making, especially
supporting the decisions of unexperienced clinicians.
The objective of this paper is to perform an extensive study on
differential diagnostics of dementias utilizing only structural MRI data.
We evaluate several state of the art automatic quantiﬁcation methods
in order to ﬁnd out which of the methods or what combination gives
optimal classiﬁcation accuracy. We utilize a dataset of 504 patients
divided into ﬁve different groups: controls (CN), AD, FTD, DLB, and
VaD. Both T1 and FLAIR data are used in the analysis.
2. Material and methods
2.1. Patient groups
We study a total of 504 patients from the Amsterdam Dementia
Cohort who had visited the Alzheimer center of the VU UniversityMedical Center between 2004 and 2014 (van der Flier et al., 2014).
The patients were included if MRI andmini mental state examination
(MMSE) (Folstein et al., 1975) were present. At baseline, all patients
received a standardized and multi-disciplinary work-up, including
medical history, physical, neurological and neuropsychological
examination, MRI, laboratory test and lumbar puncture to collect
cerebrospinal ﬂuid. Diagnoses were made in a multidisciplinary
consensus meeting.
In this study, patients with subjective cognitive decline (SCD) were
regarded as the control subjects. Patients were diagnosed as having
SCD when cognitive complaints could not be conﬁrmed by cognitive
testing and criteria for MCI, dementia or other neurological or psychiat-
ric disorder known to cause cognitive complaintswere notmet. Patients
were diagnosed with probable AD using the criteria of the National
Institute for Neurological and Communicative Diseases Alzheimer's
Disease and Related Disorders Association; all patients also met the
core clinical criteria of the National Institute on Aging-Alzheimer's
Association guidelines for AD (McKhann et al., 1984; McKhann et al.,
2011). FTD was diagnosed using the Neary criteria; patients also met
the core criteria from Rasckovsky (Neary et al., 1998; Rascovsky et al.,
2011). VaD was diagnosed using the National Institute of Neurological
Disorders and Stroke and Association Internationale pour la Recherché
et l'Enseignement en Neurosciences criteria (Román et al., 1993), and
DLB using the McKeith criteria (McKeith et al., 1996; McKeith et al.,
2005). The studywas approved by the local Medical Ethical Committee.
All patients have signed written informed consent for their clinical data
to be used for research purposes.
The normal cognition of all the SCD patients was conﬁrmed at 9
months follow-up. Follow-up took place by annual routine visits to
the memory clinic in which patient history, cognitive tests and a
general physical and neurologic examination were repeated.
Follow-up data was available in all SCD subjects, with a mean of
2.5±1.4 years.2.2. Imaging
Subjects were scanned routinely on either 1.0 T, 1.5 T or 3.0 T MRI
devices. All scans include a 3-dimensional T1-weighted gradient echo
sequence and a fast FLAIR sequence. The voxel size of the T1-images
varies between 0.9×0.9×0.9 mm3 and 1.1×1.1×1.5 mm3. For FLAIR
images there is much more variation in the slice thickness, as the
voxel size varies between 0.4×0.4×1.0 mm3 and 1.2×1.2×5.0 mm3.
86 patients were imaged using 1.0 T device, whereas 1.5 T and 3.0 T de-
viceswere used for the remaining 97 and 321 patients, respectively. De-
tailed information on the imaging parameters for each disease group is
available in Appendix A.
Imaging data were assessed visually for atrophy and vascular
changes. Visual rating of medial temporal lobe atrophy was per-
formed on coronal T1-weighted images according to the 5-point
(0–4) rating scale for medial temporal lobe atrophy (MTA) from
the average score of the left and right sides (Scheltens et al., 1995).
Global cortical atrophy (GCA) was assessed visually on axial FLAIR
images (possible range of scores 0–3) (Pasquier et al., 1996). The
degree of severity of white matter hyperintensities was rated on
axial FLAIR images using Fazekas' scale (possible range of scores
0–3) (Fazekas et al., 1987). The number of lacunes (# of lacunes)
was deﬁned as T1-hypointense and T2-hyperintense CSF-like lesions
surrounded by white matter or subcortical gray matter. Next to an
overall count of lacunes, the presence of ≥1 lacunes in the basal
ganglia (BG lacunes) was determined. Finally, the presence of
infarcts ≥1 (Infarcts) was visually evaluated.
In this study, the visual scores serve as reference values: the multi-
class classiﬁcation is performed using visual scores (Section 3.1) and
the results obtained with automatic image quantiﬁcation methods
(Section 3.2) are compared against these results.
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Automated image quantiﬁcation tools used in thiswork require atlas
data. For this purpose we use a set of 60 subjects from the ADNI
database (http://adni.loni.usc.edu/), consisting of 20 elderly healthy
controls, 20 mild-cognitive impairment subjects and 20 AD subjects.
For each atlas image (T1 MR images of the 60 subjects), a whole brain
segmentation (http://www.neuromorphometrics.com/) containing
139 regions (98 cortical parcellations and 41 sub-cortical regions) was
generated. In addition, in order to produce more accurate segmenta-
tions for hippocampus, the semi-automatic hippocampus segmenta-
tions of the ADNI database are used as atlas segmentations as done in
(Lötjönen et al., 2010, 2011).
Amean anatomical template generated from30ADNI images is used
as the reference image in the morphometric analyses (Guimond et al.,
2000; Koikkalainen et al., 2011).2.4. Image quantiﬁcation methods
Several fully automatic image quantiﬁcation methods are tested to
quantify different aspects of images: 1) volumetry using multi-atlas
segmentation, 2) atrophy of brain tissue using voxel-based morphome-
try (VBM) and tensor-based morphometry (TBM), 3) similarities with
database images using manifold learning and ROI-based grading, and
4) vascular changes by segmentation of white matter hyperintensities
and cortical and lacunar infarcts.2.4.1. Pre-processing
T1-weighted images are ﬁrst re-sampled to 1 mm isotropic voxels.
Then, the images are skull-stripped, bias ﬁeld corrected, and intensities
normalized using in-house software tools. The segmentation of brain
tissue into white matter (WM), grey matter (GM), and cerebrospinal
ﬂuid (CSF) is done based on the Expectation-Maximization (EM)
algorithm (Leemput et al., 1999).
FLAIR images are bias corrected using ITK's N4 bias ﬁeld correction
algorithm (Tustison et al., 2010). For the registration of T1 and FLAIR
images, the FLAIR images are re-sampled to 1 mm isotropic voxels.
After that, T1 images are registered to FLAIR images by maximizing
Normalized Mutual Information (NMI) (Studholme et al., 1999) using
gradient ascent. This transformation is used to transform the results of
the T1 images to FLAIR coordinates.Fig. 1. An example of the segmentations of T1 MR image.2.4.2. Multi-atlas segmentation
Multi-atlas segmentation methods have been proven to produce
robust and accurate segmentations of brain structures (Heckemann
et al., 2006; Aljabar et al., 2009; Lötjönen et al., 2010; van Rikxoort
et al., 2010). In this study, multi-atlas segmentation is used to segment
hippocampus and to segment the whole brain into 139 regions using
the atlases presented in Section 2.3.
The segmentation method is presented in (Lötjönen et al.,
2010, 2011) and was extended by local weighting of atlases
(Artaechevarria et al., 2009). In this method, the T1 image of a pa-
tient and the atlases are ﬁrst registered using coarse non-rigid de-
formation. Then, an atlas selection is used to select 12 atlases out of
the 60 atlases for more detailed non-rigid registration. A probabi-
listic atlas, generated from these atlas segmentations, is used as a
prior in the intensity-based classiﬁcation using the EM algorithm
(Lötjönen et al., 2010). An example of the segmentation results is
given in Fig. 1.
The following volumetric features are obtained from the
multi-atlas segmentation: volumes of left and right hippocampus
and the total hippocampal volume, and the volumes of 139 brain
regions.2.4.3. Voxel-based morphometry
VBM is a technique where the local concentration of GM is mea-
sured after accounting for global differences in anatomy by register-
ing a patient image to a reference image (Ashburner and Friston,
2000).
In VBM, the registration of the patient's T1 image to the reference
image is usually performed using a coarse non-linear registration
approach. Here, registration parameters that result in a coarse match
of the reference and patient images are used. Further details regarding
the registration method used can be found in (Lötjönen et al., 2010).
The GM segmentation of the patient is propagated to the reference
space according to the calculated transformation. The GM segmentation
is then smoothed using a Gaussian ﬁlter (σ=4 mm) to produce a
measure of GM concentration for each voxel.
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features for classiﬁcation, the features are computed by combining the
data within each of 139 regions of interest (ROIs). In addition, a global
feature for the whole brain is computed by using the whole brain as a
ROI. If the GM concentration is simply averaged ROI-wise, there can
be inside a ROI both voxels where the GM concentration is higher in
one disease group as compared to the other, and voxels where the
GM concentration is lower. Consequently, the averaging would cancel
these two opposite effects. Because of this, the GM concentration is
computed separately for the voxels with typically higher or lower GM
concentration, and then these values are summed up with different
signs:
FVBMi; j Rð Þ ¼
X
p!∈R∩ Ti; j p!
 
N0
 W p!
 
 GM p!
 
−
X
p!∈R∩ Ti; j p!
 
b0
 W p!
 
 GM p!
 
X
p!∈RW p
!  ;
ð1Þ
where R deﬁnes the ROI, i and j deﬁne the two diseases studied,GMð p!Þ
is the GM concentration for voxel p!, Ti; jð p!Þ is the t-value from the
group-level t-test (comparison of the two diseases), and Wð p!Þ is a
weighting function deﬁned as
W p!
 
¼
1; if Pi; j p
! 
b0:000001
0; if Pi; j p
! 
N0:05
log 0:05ð Þ− log Pi; j p!
  
log 0:05ð Þ− log 0:000001ð Þ ; otherwise
8>>><
>>>:
; ð2Þ
where Pi; jð p!Þ is the p-value of the t-test. Note that the VBM features
are computed for each pair-wise comparison of two diseases in order
to extract information only from those regions with relevant infor-
mation for the particular pair of diseases. The p- and t-values are
computed by applying the t-test on GM concentration data of a sep-
arate training set consisting of patients from the two disease groups i
and j.
Consequently, 139ROI-wise and oneglobal VBM features are obtain-
ed for each pair-wise comparison of diseases, i.e., in total 20 sets of VBM
features for ﬁve groups. Note that Fi , jVBM(R)= -Fj , iVBM(R), so in practice
only 10 sets of features need to be computed.
2.4.4. Tensor-based morphometry
An alternative approach to VBM is to characterize differences in
brain morphometry using TBM. In TBM, the reference image is
registered to the patient image using high-dimensional registration,
and the analysis is done by comparing measures derived from the
deformation ﬁelds (Ashburner et al., 1998). In this study, the same
registration method that is used in VBM is used in the TBM analysis,
but the parameters are chosen to perform the registration at a ﬁner
level of detail. The local volume difference as compared to the reference
is used to quantify the non-rigid deformation by computing the
determinant of the Jacobian matrix:
J p!
 
¼
∂Dx p
! 
∂x
∂Dx p
! 
∂y
∂Dx p
! 
∂z
∂Dy p
! 
∂x
∂Dy p
! 
∂y
∂Dy p
! 
∂z
∂Dz p
! 
∂x
∂Dz p
! 
∂y
∂Dz p
! 
∂z


; ð3Þ
whereDxð p!Þ,Dyð p!Þ, andDzð p!Þgive the deformation from the reference
to the patient image in x-, y-, and z-directions for voxel p!.The features are computed as in the VBM analysis. The
only difference is that the GM concentration in Eq. (1) is
replaced by the logarithm of the Jacobian logð Jð p!ÞÞ. The loga-
rithm is used to make the Jacobians more normally distributed
and treat contraction and expansion in a similar fashion. As in
the VBM analysis, the t-test is applied to a training set to produce
t- and p-values for the feature computation. The TBM analysis
produces in total 140 features for each comparison of two
diseases.
2.4.5. Manifold learning
A fundamental problem when dealing with high-dimensional
data such as 3D brain MR images is the large amount of variables
(for example, over 16 million voxels for a 256×256×256 image)
available in images, where not all contain equal (or any) desired
information. Manifold learning aims at ﬁnding a low-dimensional
representation of high-dimensional data while trying to faithfully
represent the intrinsic local geometry of the data. In (Guerrero
et al., 2014;Wolz et al., 2011) manifold learning was used in the con-
text of neurodegenerative disease population modeling to extract a
meaningful low-dimensional representation better suited for
classiﬁcation.
Laplacian eigenmaps (Belkin andNiyogi, 2002) can be used to derive
a mapping from a high-dimensional space RD to a low-dimensional
space Rd that best represents a population X, such that d≪D. Here
local geometry is determined by converting pairwise sum of squared
differences (SSD) to a similarity matrix G using a Gaussian heat kernel.
From G, the k-neighborhoods of data points are used to construct a
sparse neighborhood matrix W. Laplacian eigenmaps seeks to place
points xs and xr close together in Rd if they are close in the original RD
space (large similarity ws ,r). This is achieved by means of minimizing
ϕ(Y)=argmin∑s ,r ∥ys -yr∥2ws ,r under the constraint that yTLy=1,
where y are the calculatedmanifold coordinates. This can be formulated
as generalized eigenproblem Lν=μMν, where L=M-W is the
graph Laplacian and M is a degree matrix. Here ν and μ are the
eigenvectors and eigenvalues, where the d eigenvectors corresponding
to the smallest (non-zero) eigenvalues represent the new coordinate
system.
In this study two ROIs are utilized in manifold learning: one for
hippocampus region and one for frontotemporal lobe region
(Fig. 2). The ROIs were generated by dilating ten times the segmen-
tations for hippocampus and temporal pole. In the classiﬁcation,
ten eigenvectors are used, consequently resulting in ten features
for both ROIs.
2.4.6. ROI-based grading
In ROI-based grading, the idea is to propagate disease labels of
training subjects to test subjects and assign disease scores for the
test subjects. Given the training population, the relationship be-
tween each test subject and the training population is investigated
so that the disease information of the training population can be
propagated to test subjects. The grading features are calculated
based on the methods proposed in (Coupé et al., 2012; Tong et al.,
2013).
In (Coupé et al., 2012), the relationship is modeled using a
weighting function. Here, we model this relationship using a
sparse representation method, which has been demonstrated to
be superior to the weighting function in image segmentation
(Tong et al., 2013). Data of each test subject is assumed to lie in
the space of the training population and be represented by a lin-
ear combination of the data from few training subjects. In order
to seek a sparse representation of the data of each test subject,
we utilize the Elastic Net sparse coding technique as in (Tong
et al., 2013). Given the intensities of a test subject Xtest∈Rk×1
and the intensities of n training subjects Xtraining∈Rk×n in a ROI,
Fig. 2. ROIs used for manifold learning and ROI-based grading: red = hippocampus region, blue = frontotemporal lobe region, purple = ROIs overlapping. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. An example of segmentation of a FLAIR image.
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minimizing the following cost function:
α ̂ ¼ min
α
1
2
jXtest−Xtrainingαjj
2
2 þ λ1jjαjj1 þ
λ2
2
jαjj
2
2
gtest ¼
Xn
s¼1αt sð ÞlsXn
s¼1αt sð Þ
:
8>>><
>>>:
ð4Þ
Here α ̂ are the coding coefﬁcients of the test subject and ls is the
disease label vector for the sth training subject. Each training label
vector is deﬁned as ls=[0,0…1…0,0], where the non-zero
entry position indicates the disease label of a speciﬁc group.
Most of the coefﬁcients in α are zero due to the sparsity
constraint. If the sth coefﬁcient in α is not zero, it indicates that the
corresponding sth training subject has been selected to propagate
its clinical label information to the test subject. Finally, the calculated
grading scores can be used as features for classiﬁcation. The same
ROIs that are used in manifold learning are used also in ROI-based
grading.
2.4.7. Segmentation of white matter hyperintensities
The segmentation of white matter hyperintensities (WMH) is done
according to the method presented in (Wang et al., 2012). The method
is based on the EM algorithm, and the segmentation is done in three
steps:
1. Segment WM in two classes from T1 image representing hypointense
WM regions in T1 image and normal bright WM regions.
2. Using the results of the previous step as an initialization, segment the
FLAIR image to three classes: CSF, normal brain tissue, and hyperin-
tense voxels.
3. Using the results of the previous step as an initialization, segment the
WMand subcortical regions from the FLAIR image in two classes. The
class with higher intensities was then regarded as the segmentation
of WMH.
The segmentations ofWM, CSF, and subcortical regions are obtained
from the segmentation of T1 image (Sections 2.4.1 and 2.4.2). An
example of the WMH segmentation is shown in Fig. 3.
Instead of the raw total WMH volume, a masked WMH volume is
computed in order to provide better discriminatory information. A
mask was generated that includes only voxels that are brighter than
the 99.3% percentile of the intensities inside the brain and are located
inside the centrum semiovale. The masked WMH volume is computed
as the WMH volume inside the mask. The parameter for the threshold
was determined by testing several values. The centrum semiovale was
deﬁned from the MNI 152-template: ﬁrst, the white matter superior
to the lateral ventricles (zN32) was extracted, and then the sulcal
white matter regions were removed using a set of morphological
operations. The segmentation of centrum semiovale is propagated tothe patient images based on MNI-to-reference and reference-to-
patient registrations.
2.4.8. Segmentation of cortical infacortical infarcts
Cortical infarcts are segmented as the hyperintense regions in FLAIR
images that are partly located in cortex. The segmentation of the cortex
is obtained from the multi-atlas segmentation of the T1 image
(Section 2.4.2, segmentation method evaluated in (Lötjönen et al.,
2010, 2011)) and the threshold for the segmentation is computed
utilizing the WMH segmentation. The total volume of cortical infarcts
is computed from the segmentation.
2.4.9. Segmentation of lacunar infarcts
A method was developed for the segmentation of lacunar
infarcts utilizing both FLAIR and T1 images. The method ﬁrst detects
candidate locations via localizing “holes” in a T1 image, and then
classiﬁes these holes based on the intensities and contrasts in T1 and
FLAIR images.
In order to ﬁnd the holes, the tissue segmentation of T1 image is
performed using two approaches: 1) EM-based classiﬁcation and
2) multi-atlas segmentation as in Section 2.4.2. EM-classiﬁcation is
based mostly on the voxel intensities, i.e., a voxel with low intensity
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easily misclassiﬁed in multi-atlas segmentation if they are in the
middle of WM and a strong probabilistic prior term is used.
Consequently, holes can be detected as the voxels that are classiﬁed
as CSF in EM-classiﬁcation and as WM or GM in multi-atlas
segmentation.
A hole is classiﬁed as a lacunar infarct if 1) in FLAIR, the contrast of
the hole and the surrounding tissue is large, 2) the surrounding tissue
in FLAIR is bright, and 3) the intensity in T1 image is low. However, in
basal ganglia the condition 2 is not expected. Finally, only the infarcts
with diameter larger than 3 mm and smaller than 15 mm are regarded
as lacunar infarcts.2.4.10. Vascular burden measure
The clinical criteria for the diagnosis of VaD include evidence of in-
farcts, lacunar infarcts, and white matter lesions (Román et al., 1993),
but all of these ﬁndings are not needed for the diagnosis. To mimic
these criteria, a vascular burden measure is computed to take into ac-
count the fact that, for example, a patient with no lacunar infarcts can
be diagnosed as VaD:
Vascular burden ¼masked WMH volume þ volume of cortical infarcts
þ 300  volume of lacunar infarcts:
ð5Þ
In other words, all the volumes are summed up, but because of the
small volume of the lacunar infarcts they are given an empirically
determined larger weight. This measure is used as a classiﬁcation
feature.2.5. Normalization of features
The classiﬁcation features are adjusted for covariates to take into
account normal age- and gender-related differences. The covariate ad-
justment is performed by ﬁtting a multi-dimensional linear regression
model to the distribution of the feature values of the control group
using age and gender as independent variables. Only control data are
used here so that any disease-related effects would not be removed.
The feature values of each patient are then normalized using the
obtained regression parameters according to patient's age and gender
(Koikkalainen et al., 2012).
In addition, it was noticed that the images acquired with the
1.0 T MRI device produce systematic differences as compared to
the remaining images. Consequently, an additional binary indepen-
dent variable is added to the normalization that removes this
systematic error from the feature values and makes it possible to
simultaneously analyze images acquired with different MRI
devices.Table 1
A summary of the training set features used to compute the DSI(i, j) for each disease-pair.
Features Description
Volumes 142 Left, right and total hippocampus, 139 regions
from atlas
TBM 140 For each disease-pair comparison features for
139 ROIs and a global feature
VBM 140 For each disease-pair comparison features for
139 ROIs and a global feature
Manifold learning 20 Number of manifold dimensions (10) × number
of ROIs (2)
ROI-based grading 8 Number of classes (4) × number of ROIs (2)
Vascular burden 1 Vascular burden measure2.6. Classiﬁcation
The classiﬁcation based on the quantiﬁed MRI biomarkers is
performed using amodiﬁcation of the Disease State Index (DSI) classiﬁ-
er (Mattila et al., 2011, 2012) that has been originally developed for
two-class problems. For this application, the classiﬁer is modiﬁed for
multi-class classiﬁcation. The classiﬁer is described in detail in
Appendix B. The classiﬁer gives as an output a continuous index be-
tween zero and one, DSI(i, j), for each comparison of two classes i and
j. This index describes the likelihood that the patient belongs to class j
when class i is an alternative option. From these pair-wise DSI values,
total DSI values DSI(i) are computed describing the likelihood that the
patient belongs to the class i. Finally, the patient is assigned to the
class with the highest index value.2.7. Evaluation
The classiﬁcation accuracy is evaluated using 10-fold cross-
validation. In practice, 10 percent of the patients are randomly
selected as a test set, and the remaining 90% are used as a training
set. The training set is used to compute the t-tests needed for the
computation of VBM and TBM features (Eqs. (1) and (2)), to
compute the ROI-based grading features, and to compute the nor-
malization parameters (Section 2.5). In addition, the classiﬁer is
trained using the features of the training set and then applied to
the test set. This is repeated ten times so that each patient is once
used in the test set.
The classiﬁcation results of the test set are compared to the clinical
diagnoses using two measures: classiﬁcation accuracy (acc) and
balanced accuracy (Brodersen et al., 2010) (Bacc):
acc ¼
XNc
i¼1# of correctly classified patients of disease i
# of all patients
; ð6Þ
Bacc ¼ 1
Nc
XNc
i¼1
# of correctly classified patients of disease i
# of patients with disease i
: ð7Þ
The balanced accuracy is used to take into account the imbalance
in the number of cases between different classes, reﬂecting the
prevalence of diseases. For example, the training data of this
study contains more AD patients than FTD, DLB and VaD patients
altogether leading to the situation that classifying all patients as AD
produces already relatively good classiﬁcation accuracy. The bal-
anced accuracy is an estimate of the accuracy the classiﬁer would
achieve on a data set consisting of an equal amount of patients in
each class.
Because the vascular changes are characteristics to VaD, and there
are no VaD speciﬁc structural changes, only the vascular burden
measure is included in the training set for the VaD patients. In prac-
tice this means that the classiﬁer does not use structural features
when VaD is one of the two diseases compared. However, all the
data are used for the VaD training patients in the evaluations
where the vascular burden measure is not used in order to enable
fair comparison between methods. For example, when evaluating
the performance of VBM alone, the VBM data are used for the VaD
training patients. Otherwise, there would be no data for VaD patients
in the training set and consequently all VaD patients in the test set
would be misclassiﬁed.
Also in the ROI-based grading the VaD training data are not used,
and consequently the number of features for each ROI is four. For TBM
and VBM training data, only the features from the pair-wise comparison
Fi , j
VBM/TBM are used when the DSI(i, j) is computed. The training set
Table 2
Clinical data and visual MRI ratings for the patient groups. Data presented in mean ± standard deviation or number (percentage). MTA=Medial temporal lobe atrophy, GCA= Global
cortical atrophy, # of lacunes = number of lacunar infarcts, BG lacunes = presence of lacunar infarcts in basal ganglia.
Total CN AD FTD DLB VaD
N 504 118 223 92 47 24
Age 64 ± 8 60 ± 8b,c,d,e 66 ± 7a,c 63 ± 7a,b,d,e 68 ± 9a,c 68 ± 6a,c
Females 221 (44%) 45 (38%)b,d 120 (54%)a,d 41 (44%)d 6 (13%)a,b,c,e 9 (38%)d
MMSE 23 ± 5 28 ± 1b,c,d,e 21 ± 5a,c,d,e 25 ± 5a,b 23 ± 4a,b 24 ± 5a,b
MTA 1.1 ± 0.9 0.3 ± 0.5b,c,d,e 1.3 ± 0.8a,c,d 1.8 ± 1.0a,b,d,e 0.8 ± 0.7a,b,c,e 1.3 ± 0.9a,c,d
GCA 0.9 ± 0.7 0.3 ± 0.5b,c,d,e 1.0 ± 0.6a 1.2 ± 0.8a 1.0 ± 0.7a 0.8 ± 0.7a
Fazekas 0.9 ± 0.9 0.6 ± 0.7b,d,e 1.0±0.8a,c,e 0.7±0.8b,d,e 0.9 ± 0.7a,c,e 2.4 ± 0.8a,b,c,d
# of lacunes 0.3 ± 1.7 0.1 ± 0.3e 0.2 ± 1.5e 0.2±.0.8e 0.0 ± 0.2e 4.3 ± 4.5a,b,c,d
BG lacunes 31 (6%) 5 (4%)e 6 (3%)e 3 (3%)e 2 (4%)e 15 (63%)a,b,c,d
Infarcts 16 (3%) 1 (1%)e 15 (2%)e 2 (2%)e 0 (0%)e 8 (33%)a,b,c,d
Statistically signiﬁcant (pb0.05) differences between the patient groups were studied using the Mann-Whitney U test for age, MMSE, MTA, GCA, Fazekas rating, and number of lacunes.
Chi-squared test was used for the gender, presence of lacunes in basal ganglia and presence of infarcts.
a Statistically signiﬁcantly different from CN.
b Statistically signiﬁcantly different from AD.
c Statistically signiﬁcantly different from FTD.
d Statistically signiﬁcantly different from DLB.
e Statistically signiﬁcantly different from VaD.
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However, for the test set patients the full set of features is always
given to the classiﬁer.
In order to compare the performance of the automatically
determined features with the visual MRI ratings, the DSI classiﬁer is
also used to classify the patients by utilizing the raw values of the visual
MRI ratings as the classiﬁcation features.3. Results
3.1. Clinical data and visual MRI ratings
The summary of clinical data and visual MRI ratings is presented in
Table 2.
The control and FTD groups are the youngest ones, whereas the DLB
patients aremostlymales. The highest proportion of females is in theAD
group. The AD group has lower MMSE scores than the other patient
groups.
Visual atrophy ratings MTA and GCA show atrophy for each disease,
and the FTD group has the highest atrophy values. GCA does not show
any statistical differences between the diseases while MTA does.
Fazekas rating shows most white matter lesions for VaD, for which the
differences to other groups are statistically signiﬁcant. Also AD and
DLB groups have larger Fazekas scores than the control group. VaD
patients have statistically signiﬁcantly more infarcts than other groups.
No difference in the number of infarcts was observed in AD, FTD and
DLB groups when compared with the control group.
The classiﬁcation of disease groups using the visualMRI ratings gives
a classiﬁcation accuracy of 44.6% and balanced accuracy of 51.6%. The
confusion matrix of the classiﬁcations is presented in Table 3. ForTable 3
Confusion matrix of the classiﬁcation results using visual ratings. Both the absolute and
relative classiﬁcation results are presented. Each rowshows the clinical diagnosis and each
column shows the suggested diagnosis by the classiﬁer.
CN AD FTD DLB VaD CN AD FTD DLB VaD
CN 77 8 0 28 5 CN 65% 7% 0% 24% 4%
AD 25 65 62 64 7 AD 11% 29% 28% 29% 3%
FTD 8 21 46 13 4 FTD 9% 23% 50% 14% 4%
DLB 9 13 3 20 2 DLB 19% 28% 6% 43% 4%
VaD 0 3 1 3 17 VaD 0% 13% 4% 13% 71%comparison, a balanced accuracy of 20% is obtained by randomly
assigning one of the ﬁve classes to each subject.3.2. Automatic MRI Results
Classiﬁcation results for the individual quantiﬁcation methods and
for the combined analysis using all the features are presented in
Table 4. The classiﬁcation accuracy using all the features is 70.6% and
the balanced accuracy 69.1%. The best individual quantiﬁcation method
is VBM.
Detailed results for each combination of quantiﬁcation methods
and for each pair of diseases are presented in Appendix C. It is evi-
dent that a combination of more than one quantiﬁcation method is
needed to obtain good balanced accuracy. This is affected by the
fact that no structural features are used for the VaD patients in the
training set. Consequently, vascular burden measure is needed to
produce high balanced accuracy values. The best balanced accuracy
is obtained by combining ﬁve quantiﬁcation methods. However, al-
ready the combination of ROI-based grading or VBM and vascular
burden measure gives a balanced accuracy over 67% that is relatively
close to the best result (69.2%).
The best individual features for each pair of diseases are given in
Appendix D. The ROI-based grading features and the global VBM and
TBM features were often among the best features. Individual ROIs
from medial temporal lobe, frontal lobe, ventricles and cerebral white
matter performed well in speciﬁc comparisons.
Appendix A summarizes the classiﬁcation results for different sub-
groups of imaging data. These results do not reveal major dependencies
between classiﬁcation results and imaging parameters when also the
miss-balance of the disease groups is considered. Furthermore, theseTable 4
Classiﬁcation accuracies for all features and different quantiﬁcation methods. ( ⁎All data
used for the VaD patients in training set.)
acc Bacc
All features 70.6 69.1
Volumes 50.4* 50.7*
VBM 65.1* 57.4*
TBM 64.3* 53.8*
Manifold learning 50.4* 44.5*
ROI-based grading 58.3* 51.5*
Vascular burden measure 32.7 36.2
Table 5
Confusion matrix of the classiﬁcation results using all features. Both the absolute and rel-
ative classiﬁcation results are presented. Each row shows the clinical diagnosis and each
column shows the suggested diagnosis by the classiﬁer.
CN AD FTD DLB VaD CN AD FTD DLB VaD
CN 97 10 2 9 0 CN 82% 8% 2% 8% 0%
AD 14 164 14 12 19 AD 6% 74% 6% 5% 9%
FTD 6 19 57 5 5 FTD 7% 21% 62% 5% 5%
DLB 8 18 4 15 2 DLB 17% 38% 9% 32% 4%
VaD 0 0 0 1 23 VaD 0% 0% 0% 4% 96%
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scanner type, resolution, and parameters used.
We also tested the combination of visual MRI ratings and automati-
cally determined features, but this did not improve the classiﬁcation
results obtained using only automatic image quantiﬁcation methods.
The accuracy was the same, but the balanced accuracy was slightly
worse when visual ratings were included in the classiﬁcation.
The confusion matrix of the classiﬁcations using all features is
presented in Table 5. The best sensitivity is obtained for VaD for which
only one patient is classiﬁed as DLB. Also controls are classiﬁed
accurately. Seventy four percent of the AD patients are correctly
classiﬁed, and the misclassiﬁed patients are equally distributed among
the other disease classes. The FTD patients are mostly misclassiﬁed as
AD patients. The most difﬁcult dementia to classify correctly is DLB,
which is a predictable result as there are no clear DLB-speciﬁc structural
changes. Themiss-classiﬁedDLB patients aremost often classiﬁed as AD
patients.Fig. 4. Examples of pair-wise t-maps for TBM. Red= smaller local volume in latter group,
blue= larger local volume in latter group. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)In TBM and VBM, the features are computed utilizing the
information on the locations where there are structural differences
between the two disease groups studied. Figs. 4 and 5 show the maps
of t-values for three disease-pair comparisons. Both TBM and VBM
show large regions with structural differences between AD/FTD
and controls. In TBM, the comparison of AD and FTD patients clearly
shows increased atrophy in frontal and temporal lobes in FTD
that can be used to differentiate these two diseases. Similarly, VBM
shows decreased GM concentration in the frontal and temporal lobes
for FTD.
Fig. 6 shows examples of correctly classiﬁed patients. The control
subject shows well-preserved brain anatomy, whereas the AD patient
has enlarged ventricles and medial temporal lobe atrophy. The FTD
patient has large atrophy in the frontal and temporal lobes and enlarged
ventricles. The VaD patient has vast regions ofWMH that can be seen as
bright regions in FLAIR image but also as hypointense regions in T1
image. The VaD patient has also notable brain atrophy, but the vascular
ﬁndings dominate the DSI computation, and therefore the patient is
classiﬁed as VaD.
Fig. 7 shows examples of the misclassiﬁed patients. The ﬁrst case
shows an AD patient that is classiﬁed as VaD because of the large
WMH regions clearly visible in FLAIR image. The patients miss-
classiﬁed as AD have typical brain atrophy patterns to AD, and the AD
patient classiﬁed as FTD patient has atrophy also in frontal lobe.
The DSI values for each class are also presented in Figs. 6 and 7. For
the correctly classiﬁed patients in Fig. 6, the difference between the
DSI of the correct class and the second highest DSI is large, indicating
that the patient can be diagnosed with high likelihood to the ﬁrst
class. It can be seen that even for the most obvious DLB patients theFig. 5. Examples of pair-wise t-maps for VBM. Red = smaller local GM concentration in
latter group, blue = larger local GM concentration in latter group. (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
Fig. 6. Examples of correctly classiﬁed patients with high likelihood.
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nosis to DLB cannot be donewith high conﬁdence using only imaging
data. These results demonstrate the usability of the continuous indi-
ces that describe the likelihood of each type of dementia and, there-
fore, provide information to support clinical decision making. For
example, for 50.4% of the patients the difference of the two largest
DSI values is more than 0.06. For this subset of patients the classiﬁca-
tion accuracy is 80.7%, i.e., much higher than for the whole dataset
(70.6%).
4. Discussion
In this paper, we performed an extensive study on differential
diagnostics of dementias using only structural MRI data. A ﬁve-class
classiﬁcation (CN, AD, FTD, VaD, and DLB groups) was done using 10-
fold cross-validation with a dataset of 504 patients. Several image
quantiﬁcation methods (volumetry, VBM, TBM, manifold learning,ROI-based grading, and vascular burden) were used to produce fea-
tures for classiﬁcation. The features were normalized to take into ac-
count age- and gender-related variation, and also the effect of MRI
ﬁeld strength was normalized. In addition, there was notable imbal-
ance in the size of the study groups, whichmeans that relatively high
accuracy could have been obtained just by assigning all patients to
the group with most patients. Therefore, in addition to the classiﬁca-
tion accuracy, the balanced accuracy was computed to adjust the
results for the imbalance in the size of the study groups in the
dataset.
A balanced classiﬁcation accuracy of 69.1% was obtained when all
the quantiﬁcation methods were combined. In practice, it may not
make sense to apply all quantiﬁcation methods. The best combination
of two quantiﬁcationmethods (ROI-based grading and vascular burden
measure) gave already high balanced classiﬁcation accuracy (67.7%)
demonstrating that a well-chosen subset of quantiﬁcation methods
has the potential to differentiate accurately dementias. It is essential to
Fig. 7. Examples of misclassiﬁed patients.
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detect VaD patients. Otherwise, VBM, TBM, and/or ROI-based grading
are reasonable choices to include in the analysis.
VaD patients could be detected with high sensitivity of 96%. Also
controls (sensitivity 82%) and AD patients (sensitivity 74%) could be
accurately classiﬁed. FTD patients were most often misclassiﬁed as AD
patients (21% of FTD patients) because of the similar pattern of medial
temporal lobe atrophy. The most difﬁcult type of dementia todifferentiatewas DLBwith sensitivity of 32% as there are noDLB speciﬁc
structural or vascular changes.
The ﬁve-class classiﬁcation was performed also using visual MRI
ratings as classiﬁcation features. The results were considerably worse
(acc = 44.6%, Bacc = 51.6%) than the results for automatically
determined features (acc = 70.6%, Bacc = 69.1%), which proves that
the automatic methods are able to quantify more detailed information
that is essential for the differentiation of the dementias.
Table A.6
Distributions of disease groups based on theMRI scanner. Also the classiﬁcation accuracies
and balanced accuracies are shown for the subsets of patients.
Total CN AD FTD DLB VaD acc Bacc
Siemens Impact 1.0 T 85 42 0 31 7 5 74.1 66.5
Siemens Sonata 1.5 T 66 12 37 9 6 2 65.2 64.1
GE Signa 1.5 T 28 2 15 6 4 1 60.7 56.3
GE Signa 3.0 T 317 61 170 41 30 15 71.9 70.2
Siemens Avanto 1.5 T 4 1 1 1 0 1 100.0 100.0
Philips Ingenuity 3.0 T 4 0 0 4 0 0 25.0 25.0
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ation of dementias (Barber et al., 1999; Varma et al., 2002; Klöppel
et al., 2008; Ishii et al., 2007; Burton et al., 2009; Munoz-Ruiz
et al., 2012). However, the comparison of different studies is very
difﬁcult, as the studied groups and the number of patients vary.
Also, most of the studies have utilized only two-class classiﬁcations,
whereas in this study we performed differential diagnosis with ﬁve
classes.
The strength of this study was that the classiﬁcation method uti-
lized here provides a continuous index for each disease describing
the likelihood that the patient has the particular disease. If the
highest index value is much larger than the second largest index
value, it is probable that the class given by the classiﬁer is correct.
If two or more diseases have indices close to each other, the clinician
cannot rely much on the results. On the other hand, as mixed pathol-
ogies are very common (33.8% of all dementia patients (Holmes
et al., 1999)), the indices might provide useful information for
mixed diagnoses.
Numerous state of the art classiﬁcation methods are able to per-
form multi-class classiﬁcation. However, most of them, such as sup-
port vector machines, work as a black box approach, where, for
example, the signiﬁcance of individual features cannot be easily in-
ferred. The key driver of the DSI concept has been the simplicity,
i.e., to keep the mathematics behind classiﬁcation simple and
easy to understand but still provide high classiﬁcation accuracy.
This objective was kept in mind also when transforming the
technology from two-class classiﬁcation problems to multi-class
classiﬁcation.
Automated quantiﬁcation methods and computerized decision
support methods provide additional objective information for
clinicians to support their diagnosis. This extra information might be
especially useful for unexperienced clinicians that do not constantly
meet patientswith different dementias in daily practice. This will equal-
ize the treatment of patients regardless of in which hospital they are
diagnosed.
In this study, the clinical assessment based on MRI data, neuro-
psychological test results, clinical information, and occasionally
cerebrospinal ﬂuid data was regarded as the gold standard, which
was used in the evaluation of automated MRI methods. The gold
standard diagnoses were made in a standardized way and according
to clinical criteria in amultidisciplinary consensus meetings. In order
to perform the classiﬁcation study, we only considered the core diag-
nosis and ignored all remarks about mixed pathologies. However,
the situation is not as straightforward in clinical practice but mixed
diagnoses are common, and the diagnosis of the dementia can be
surely conﬁrmed only in autopsy (Lopez et al., 2002; Rabinovici
et al., 2008).
The imaging data used in this study was from a memory clinical
cohort acquired during a period of about ten years. Consequently,
image quality signiﬁcantly varied. For example, data were acquired
on 1.0 T, 1.5 T, and 3.0 T systems, while slice thickness of the FLAIR
images varied between 1.0–6.5 mm. Using a more homogenous
dataset could potentially improve results. However, the use of
normal clinical imaging data shows that the proposed methods
could be used in clinical practice where the data are often sub-
optimal.
The quantiﬁcation methods could be further developed. Asym-
metry features might provide information for the discrimination of
FTD from other groups. Also, a more comprehensive set of ROIs in
manifold learning and ROI-based grading could improve the classiﬁ-
cation accuracy. The quantiﬁcation of vascular characteristics could
be further improved by including T2-weighted MR images in the
analysis (Wang et al., 2012). In addition, functional imaging modali-
ties, such as PET, SPECT, and fMRI, have proven to produce comple-
mentary information for the differential diagnostics of dementias
(Jagust, 2006; Kantarci et al., 2012; Roman and Pascual, 2012;Varma et al., 2002; Duara et al., 1999), and diffusion weighted MRI
can be used to quantify white matter damage (Zhang et al., 2009).
These imaging methods could provide valuable additional data to
the methodology presented in this paper.
Although in this paper we focused solely on imaging data, non-
imaging data, such as the results of neuropsychological tests, CSF
biomarkers and genetic data, are essential for the diagnostics of
dementias, and no diagnosis should be done based on only imaging
data. The objective of our further studies is to combine the methods
studied in this paper with all the available non-imaging data in order
to generate evenmore accurate classiﬁer for the differential diagnostics
of dementias.
This study was performed using imaging data from a single clinical
center. In the future, our objective is to study how themethods present-
ed can generalize for classifying patients from other clinical centers, and
study if the data acquired from one center could be used to classify
patients from another center.
5. Conclusions
In this paper, the differential diagnostics of the four most
common neurodegenerative diseases causing dementia, AD, FTD,
VaD, and DLB, and patients with SCD, which were regarded as the
control subjects, was studied with a large dataset and multiple
quantiﬁcation methods using T1-weighted and FLAIR MR images.
The results show that these diseases can be differentiated with a
high accuracy of 70.6% using only imaging data. Different quantiﬁca-
tion methods provide complementary information, and consequent-
ly, the best results are obtained by utilizing several quantiﬁcation
methods. The results show that automatic quantiﬁcation methods
and computerized decision support methods are feasible for clinical
practice and provide comprehensive information that may help
clinicians in the near future.
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Appendix A. Imaging parameters in each disease group
Tables A.6–A.9 show the distributions of the disease groups, and
the classiﬁcation and balance accuracies for different sub-sets of im-
aging data.
In total sixMRI deviceswere used in this dataset (Table A.6), andmost
of the patients were analyzedwith a 3.0 T device (Table A.7). None of the
ADpatientswas scannedwith the 1.0 TMRI device, and almost half of the
patients with 1.0 T MRIs were CNs. This explains the high classiﬁcation
accuracy for the 1.0 T device. On the other hand, GE Signa 1.5 T was
Fig. B.8. Visualization of the computation of the ﬁtness value. Upper ﬁgure shows the
probability distributions for the state 0 and the state 1, and lower ﬁgure shows the
curve for the ﬁtness value. The data shown here are for the volume of right
hippocampus where the state 0 is the CN group and the state 1 is the FTD group. The
dashed line shows an example for a patient with the right hippocampus volume of
1750 mm3. This feature value ﬁts better to the distribution of state 1 resulting in high
ﬁtness value.
Table A.7
Distributions of disease groups based on the ﬁeld strength. Also the classiﬁcation accura-
cies and balanced accuracies are shown for the subsets of patients.
Total CN AD FTD DLB VaD acc Bacc
1.0 T 85 42 0 31 7 5 74.1 66.5
1.5 T 98 15 53 16 10 4 65.3 65.6
3.0 T 321 16 170 45 30 15 71.3 69.4
Table A.8
Distributions of disease groups based on the resolution of T1 images. Also the classiﬁcation
accuracies and balanced accuracies are shown for the subsets of patients.
Total CN AD FTD DLB VaD acc Bacc
high 488 177 214 89 44 24 71.1 69.0
low 16 1 9 3 3 0 56.3 41.7
Table A.9
Distributions of disease groups based on the resolution of FLAIR images. Also the classiﬁ-
cation accuracies and balanced accuracies are shown for the subsets of patients.
Total CN AD FTD DLB VaD acc Bacc
high 348 58 199 44 29 18 71.8 68.2
low 156 60 24 48 18 6 68.0 67.7
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this device is lower than for other devices. In general, 3.0 T devices
seem to produce slightly better results than 1.5 T devices.
Because of themiss-balance in the distribution of the disease groups
between the MRI devices, especially the lack of AD patients scanned
with the 1.0 T device, there is a possibility that the results are biased.
However, the normalization of the features as described in Section 2.5
should reduce the risk for the bias. Also, the classiﬁcation accuracies
for the patients with 3.0 T images (Table A.7) are very similar to the
results for the whole dataset, which proves that such bias has not
affected the studies signiﬁcantly.
The images were also divided into two groups based on image
resolution. The images that have the largest voxel dimension smaller
that 1.5 mm establish the high resolution group, whereas rest of the
images are deﬁned as low resolution images. Table A.8 presents the
distributions of disease groups and classiﬁcation accuracies for the T1
resolution groups. Similarly, Table A.9 shows the results for the FLAIR
resolution groups. Most of the T1 images have high resolution. For the
small group of low resolution images, the classiﬁcation accuracies are
notably lower than for the high resolution images. However, this may
also be explained by the miss-balance of the disease groups. There is
much more low resolution FLAIR images. However, the difference in
classiﬁcation results between the high and low resolution groups is
not that large, which can be explained by the fact that the classiﬁcations
are mostly done based on the features derived from T1 images.Appendix B. Multi-class DSI classiﬁer
The DSI classiﬁer is based on the comparison of patient's feature
values to the feature values of database patients with known diagnosis
(Fig. B.8). Let us assume that the diagnosis needs to be done between
two diseases, or disease states, called ‘state 0’ and ‘state 1’. Now, the
patient data are compared to the database patients belonging to either
‘state 0’ or ‘state 1’. The comparison is done using the distributions of
the feature values in both states, and it is evaluated to which distribu-
tion the patient feature better ﬁts. If the feature value is on average
smaller in the ‘state 1’, a ﬁtness value is computed for each feature as
fitness x f
  ¼ Rstate1 xf
 
Rstate1 xf
 þ Lstate0 xf
  ; ðB:1Þwhere xf is the value of the fth feature for the patient, Rstate1(xf) is the
right integral of probability density function for ‘state 1’ and Lstate0(xf)
is the left integral of probability density function for ‘state 0’. If the pa-
tient feature value ﬁts perfectly to the distribution of ‘state 1’ and does
not ﬁt at all to the distribution of ‘state 0’, the ﬁtness value is one. On
the other hand, a value of zero indicates a perfect ﬁt with the ‘state 0’.
In addition, the importance of the features in differentiating the two
disease states is computed using the database data. In practice, this is
computed from the sensitivity and speciﬁcity of using the feature to
classify the database patients:
relevance fð Þ ¼ sensitivity fð Þ þ specificity fð Þ−1: ðB:2Þ
This value, ranging from zero to one, is called the relevance.
The ﬁtness values of all the features are combined using weighted
averaging with the relevance values as the weights:
DSI ¼
X
f
relevance fð Þ  fitness xf
 
X
f
relevance fð Þ : ðB:3Þ
This combination gives a disease state index, a value between zero
and one, that describes the likelihood of the patient belonging to the
‘state 1’when the alternative diagnosis would be ‘state 0’.
In multi-class classiﬁcation, normal two-class classiﬁcations are per-
formed between all the disease pairs. This gives a set of DSI values (in
this study 20) that describe the likelihood of a patient having thedisease
i when the alternative diagnosis would be the disease j: DSI(i,j). From
these pair-wise DSI values, the total DSI values for each disease is com-
puted by averaging the DSI's of the disease pair analyses:
DSI ið Þ ¼ 1
Nc  1
XNc ; j≠i
j¼1 DSI i; jð Þ; ðB:4Þ
where Nc is the number of diseases groups. This value gives a likelihood
index of patient having the disease i. When performingmulti-class clas-
siﬁcation, the patient is assigned to the class with the highest DSI(i)
value.
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CN CN CN CN AD AD AD FTD FTD VaD
vs. vs. vs. vs. vs. vs. vs. vs. vs. vs.
AD FTD VaD DLB FTD VaD DLB VaD DLB DLB
tbm 53.8a 86.9 88.6 87.9a 78.5 76.0 73.2a 63.7 84.2a 78.0 77.0a
vbm 57.4a 86.1 89.3 90.4a 83.6 76.6 73.9a 65.4 84.1a 78.0 73.8a
vol 50.7a 75.5 82.5 81.9a 74.1 70.9 74.6a 63.9 84.1a 71.0 75.7a
vasc 36.2 60.8 53.6 95.8 38.0 55.8 91.7 59.0 95.7 52.7 94.7
ml 44.5a 87.4 85.4 82.3a 69.0 77.4 60.9a 62.5 73.9a 73.6 61.1a
grading 51.5a 91.1 88.5 84.9a 74.7 82.5 68.4a 71.2 80.3a 80.6 60.0a
tbm + vbm 60.4a 87.4 88.9 93.7 83.4 79.1 77.4a 67.6 92.0a 78.0 80.1a
tbm + vol 57.1a 87.3 88.6 93.3a 78.8 75.8 80.1a 68.6 85.2a 74.8 86.3a
tbm + vasc 64.2 87.1 88.3 97.1 78.1 76.3 93.2 63.7 95.2 77.5 95.8
tbm +ml 55.1a 88.4 89.1 87.5 78.1 77.8 73.2 65.6 86.9a 78.5 79.1a
tbm + grading 55.4a 88.6 89.7 90.0a 77.7 78.4 75.3 62.6 84.8a 78.0 77.0a
vbm + vol 60.0a 87.4 91.3 92.9a 84.1 76.2 77.4a 68.6 88.9a 80.1 81.1a
vbm + vasc 67.0 85.7 88.9 97.1 84.3 76.6 94.1 65.8 95.2 78.0 95.8
vbm +ml 59.0a 86.9 89.3 90.4a 83.2 78.7 74.2a 66.2 86.8a 77.5 73.8a
vbm + grading 59.3a 87.6 89.7 89.9a 83.2 77.5 74.4a 66.8 86.8a 76.9 74.8a
vol + vasc 59.4 75.1 82.5 97.5 74.3 70.4 93.4 64.4 94.7 70.4 95.8
vol + ml 52.5a 77.5 84.0 84.4a 73.0 72.7 77.6a 64.4 79.8a 71.0 75.7a
vol + grading 53.3a 83.1 84.8 87.4a 73.3 73.6 79.7a 64.1 81.4a 71.0 73.6a
vasc + ml 60.0 87.9 85.4 97.1 70.1 78.3 93.9 63.4 95.2 72.5 95.8
vasc + grading 67.7 90.7 88.6 97.1 74.7 83.4 94.1 72.5 95.2 80.6 95.8
ml + grading 53.8a 90.5 89.6 85.3a 76.2 81.3 66.9a 71.1 73.4a 76.3 63.2a
tbm + vbm + vol 62.1a 89.0 90.2 93.3a 83.6 77.8 79.7a 66.7 89.9a 78.5 80.1a
tbm + vbm + vasc 67.5 87.5 88.6 97.1 84.1 79.5 93.9 67.6 95.2 78.0 95.8
tbm + vbm +ml 60.3a 88.7 89.4 91.6a 84.5 79.2 77.4a 68.4 92.0a 76.9 80.1a
tbm + vbm + grading 61.1a 88.3 89.8 93.7a 84.1 79.6 77.4a 69.7 92.0a 78.0 80.1a
tbm + vol + vasc 65.9 87.3 89.2 97.1 78.3 76.4 93.2 68.6 95.2 74.8 95.8
tbm + vol + ml 57.2a 87.9 90.0 93.3a 76.4 76.3 79.7a 68.6 84.7a 73.7 86.3a
tbm + vol + grading 59.7a 89.0 89.5 95.8a 78.3 78.1 79.9a 68.8 85.2 73.2 84.3a
tbm + vasc + ml 65.3 88.2 88.3 97.1 77.3 78.4 93.2 65.6 95.2 77.5 95.8
tbm + vasc + grading 64.8 88.8 88.8 97.1 77.7 79.3 93.4 62.4 95.2 76.9 95.8
tbm +ml + grading 56.2a 89.0 89.7 91.6a 78.1 79.8 75.3a 64.3 87.9a 79.6 77.0a
vbm + vol + vasc 68.1 86.6 90.4 97.1 84.7 77.1 94.1 69.3 95.2 78.0 95.8
vbm + vol + ml 61.1a 87.6 91.3 92.9a 83.2 77.1 77.6a 68.8 91.5a 79.1 79.0a
vbm + vol + grading 61.6a 89.2 90.8 92.9a 82.8 76.4 77.6a 70.1 90.9a 79.6 79.0a
vbm + vasc + ml 68.3 87.0 88.9 97.1 83.9 77.6 94.1 67.7 95.2 77.5 95.8
vbm + vasc + grading 68.9 87.4 89.7 97.1 84.3 77.5 94.1 68.4 95.2 76.9 95.8
vbm +ml + grading 59.9a 87.6 88.8 89.9a 84.3 78.6 74.4a 69.2 86.8a 76.4 74.8a
vol + vasc + ml 61.7 78.2 84.2 97.1 74.1 73.2 93.4 64.0 95.2 69.9 95.8
vol + vasc + grading 62.0 82.5 85.9 97.1 74.3 74.1 93.4 65.5 95.2 71.0 95.8
vol + ml + grading 55.0a 84.0 85.7 86.9a 74.5 77.7 78.0a 65.4 82.4a 73.1 75.7a
vasc + ml + grading 66.6 90.3 89.6 97.1 76.2 81.9 93.9 71.6 95.2 76.8 95.8
tbm + vbm + vol + vasc 68.6 88.6 89.9 97.1 84.3 78.7 93.7 67.0 95.2 77.5 95.8
tbm + vbm + vol + ml 62.2a 89.0 90.6 93.3a 83.6 78.9 79.7a 66.7 92.0a 78.5 80.1a
tbm + vbm + vol + grading 62.6a 89.0 90.6 93.3a 83.2 79.5 79.7a 67.8 89.9a 78.5 80.1a
tbm + vbm + vasc + ml 68.0 88.5 89.1 97.1 85.1 79.7 93.9 68.4 95.2 76.9 95.8
tbm + vbm + vasc + grading 68.7 88.3 89.5 97.1 84.7 80.5 93.9 69.7 95.2 78.0 95.8
tbm + vbm +ml + grading 61.0a 89.0 89.8 93.7a 83.6 79.3 77.4a 69.5 92.0a 78.0 80.1a
tbm + vol + vasc + ml 66.2 87.7 90.1 97.1 75.6 77.0 93.2 68.8 95.2 75.3 95.8
tbm + vol + vasc + grading 66.2 88.8 89.7 97.1 78.6 79.2 93.2 68.8 95.2 73.7 95.8
tbm + vol + ml + grading 59.6a 88.6 90.4 95.8a 79.0 79.5 79.9a 68.6 84.7a 73.7 84.3a
tbm + vasc + ml + grading 65.7 89.0 88.8 97.1 77.7 80.2 93.4 65.2 95.2 78.5 95.8
vbm + vol + vasc + ml 68.3 87.2 90.4 97.1 84.3 77.5 93.9 69.3 95.2 78.0 95.8
vbm + vol + vasc + grading 69.0 88.5 89.9 97.1 83.9 77.9 93.9 70.3 95.2 77.5 95.8
vbm + vol + ml + grading 62.1a 88.5 91.2 92.9a 83.9 77.9 77.6a 69.9 91.5a 78.0 79.0a
vbm + vasc + ml + grading 69.0 87.6 88.8 97.1 85.3 78.3 94.1 69.9 95.2 76.4 95.8
vol + vasc + ml + grading 63.7 83.3 85.9 97.1 75.6 78.1 93.4 67.0 95.2 73.1 95.8
tbm + vbm + vol + vasc + ml 68.9 88.6 90.3 97.1 84.3 79.3 93.7 67.0 95.2 77.5 95.8
tbm + vbm + vol + vasc + grading 69.0 88.6 90.3 97.1 83.9 80.2 93.9 68.0 95.2 77.5 95.8
tbm + vbm + vol + ml + grading 62.7a 89.0 90.6 93.3a 83.6 79.4 79.7a 67.8 92.0a 78.5 80.1a
tbm + vbm + vasc + ml + grading 68.8 89.0 89.5 97.1 84.7 80.0 93.9 69.5 95.2 78.0 95.8
tbm + vol + vasc + ml + grading 66.9 88.4 90.5 97.1 79.6 79.7 93.4 68.4 95.2 74.8 95.8
vbm + vol + vasc + ml + grading 69.2 88.1 90.3 97.1 84.5 77.5 93.9 70.3 95.2 76.9 95.8
tbm + vbm + vol + vasc + ml + grading 69.1 88.6 90.3 97.1 84.3 80.1 93.7 68.2 95.2 77.5 95.8
vol = Volumes.
vasc = Vascular burden measure.
ml = Manifold learning.
Grading = ROI-based grading.
a All data used for the VaD patients in training set.
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C
C
C
A
A
A
FT
FTFeature BaccN vs. AD Grading for CN, hippocampus region 89.7
Grading for AD, hippocampus region 88.7
VBM, Global 85.2
VBM, left cerebral white matter 82.7
TBM, left hippocampus 82.1
Grading for CN, frontal region 82.0
VBM, right cerebral white matter 81.1
VBM, right hippocampus 81.1
TBM, global 80.6
Manifold learning feature 3, hippocampus region 80.4N vs. FTD VBM, global 89.1
Grading for CN, frontal region 85.4
TBM, global 84.6
VBM, left cerebral white matter 84.6
VBM, left anterior insula 83.1
Grading for CN, hippocampus region 82.5
VBM, right cerebral white matter 81.6
TBM, left hippocampus 81.3
Volumes, left anterior insula 80.8
TBM, left entorhinal area 80.4N vs. VaD Vascular burden measure 95.8
N vs. DLB VBM, global 80.3VBM, right cerebral white matter 79.4
VBM, left cerebral white matter 76.9
Grading for CN, hippocampus region 73.5
Grading for CN, frontal region 71.8
TBM, Right Caudate 71.6
VBM, Left Planum Polare 71.6
VBM, Left Caudate 70.5
VBM, Right Caudate 69.6
VBM, Left Planum Temporale 69.2D vs. FTD Grading for AD, hippocampus region 77.1
Grading for FTD, frontal region 76.3
VBM, global 75.2
TBM, global 74.3
Grading for FTD, hippocampus region 73.8
TBM, left temporal pole 73.0
Volumes, left temporal pole 72.7
VBM, left temporal pole 72.5
VBM, left cerebral white matter 72.2
Manifold learning feature 7, hippocampus region 69.8D vs. VaD Vascular burden measure 91.7
D vs. DLB Grading for CN, hippocampus region 72.7Grading for AD, hippocampus region 71.7
Volumes, right entorhinal area 70.1
TBM, left caudate 69.5
VBM, left hippocampus 69.1
VBM, right hippocampus 67.7
VBM, right lateral ventricle 67.1
VBM, right amygdala 67.1
TBM, right amygdala 66.8
VBM, right inferior lateral ventricle 65.7D vs. VaD Vascular burden measure 95.7
D vs. DLB Grading for FTD, frontal region 76.9TBM, global 76.4
VBM, left lateral ventricle 75.8
VBM, right basal forebrain 75.8
VBM, left anterior insula 74.8
Volumes, left temporal pole 74.8
VBM, global 73.7
Grading for CN, frontal region 73.7
VBM, left fusiform gyrus 73.7
VBM, right cerebral white matter 72.7aD vs. DLB Vascular burden measure 94.7VReferences
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